Go to the profile of PharmAbcine

PharmAbcine

 

About PharmAbcine

Since PharmAbcine was established in 2008, we have been committed to developing new anti-cancer antibody drugs. Thus we have established a business foundation of various pipelines, including clinical stage new drug TTAC-0001. We have the vision to become a global biotech company by releasing new global blockbuster by 2020 through continuous growth based on the development of further pipelines. PharmaAbcine has established an innovative technology of development of fully human therapeutic antibodies by utilizing fully human non-immunologic phage display library which has been independently developed.

Therapeutic Areas

Oncology

Technologies

Drug delivery

Company Type

Biotechnology – R&D services

State of Ownership

Private

Sponsorship Group

Networker

Influencer Of

Topics

Editions participated in:

September 2019